

Netherlands economic mission to Switzerland

9 – 11 September 2025



Netherlands

Index

Foreword Vice Minister Sweers	6
Foreword President VNO-NCW Ingrid Thijssen	7
Word of Welcome Ambassador Karin Mössenlechner	8

The Netherlands

Map of the Netherlands	11
Introducing the Netherlands	12
Switzerland and the Netherlands	15

Company profiles

Biotechnology	18	Optics11Life	38
Biosynth	19	ORCA Therapeutics	39
Biotech Booster	20	Protyon	40
Bondus	21	Province of Noord-Brabant	41
chiron	22	RegMed XB	42
Demcon	23	Roche Nederland	43
GlycoMScan	24	Single Cell Discoveries	44
HAN University of Applied Sciences	25	Sync Biosystems	45
Health~Holland	26	Tetractys	46
IMS	27	Top Sector Life Sciences Health (Health~Holland)	47
Leiden Bio Science Park	28	UMC Utrecht	48
Luo Automation	29	University of Twente	49
Mimetas	30	VivArt-X	50
MosaMatrix	31	Hightech / Semicon	52
NecstGen	32	Buck Consultants International	53
Novartis Pharma	33	Ceratec Technical Ceramics	54
NXTGen Hightech	34	Demcon	55
Ombion Centre for Animal-Free Biomedical Translation	35	High Tech NL	56
Oncode Accelerator	36	Hittech Group	57
Oncolines	37		

<u>Holland High Tech</u>	58
<u>MassSpecpecD</u>	59
<u>Nedinsco</u>	60
<u>Nexperia</u>	61
<u>Nijdra Group</u>	62
<u>Nobleo</u>	63
<u>Pronexos</u>	64
<u>Province of Noord-Brabant</u>	65
<u>University of Twente – BRAINS</u>	66
<u>VDL Enabling Technologies Group</u>	67
<u>World Class Maintenance</u>	68

Contact details

<u>Ministry of Foreign Affairs</u>	71
<u>Ministry of Agriculture, Nature and Food Quality</u>	71
<u>Ministry of Health, Welfare and Sport</u>	71
<u>Ministry of Economic Affairs / Netherlands Enterprise Agency</u>	72
<u>VNO-NCW</u>	73
<u>Embassy of the Kingdom of the Netherlands</u>	74



Foreword



It is my great pleasure to lead this economic mission to Switzerland. The delegation of more than 50 leading companies and organizations represents the pinnacle of Dutch expertise in the high-tech, semicon and biotech sectors.

Switzerland is widely regarded as a hub for advanced high-tech industry and innovation – a country where products are designed and made with careful attention to quality and precision. The close collaboration between industry and research contributes to Switzerland's innovative power.

The country is internationally renowned for its strong and highly specialised sectors, such as medical technology, microtechnology and biotechnology, and it is a global leader in pharmaceuticals. The Netherlands is also a leader in biotech innovation, particularly in the fields of cell and gene therapy and regenerative medicine.

In the semiconductor sector, both countries bring complementary strengths. The Netherlands plays a vital role in global supply chains and is one of just three countries worldwide with a complete semiconductor value chain, positioning us as a global leader. Switzerland has a strong foothold in niche, high-value areas such as sensors, power management and analogue chips. These complementary capabilities open up promising opportunities for closer collaboration in the high-tech domain. By working together more closely, Dutch and Swiss companies can accelerate the development and adoption of new technologies and strengthen their innovation ecosystems.

Trade between the Netherlands and Switzerland has traditionally been robust, in part due to their locations on the Rhine. This economic mission offers an opportunity to create new partnerships, exchange ideas and enhance economic growth and resilience.

I wish all participants an inspiring and successful mission.

Michiel Sweers

Vice Minister for Foreign Trade

Foreword



It is a great honor to lead the Dutch business delegation on this economic mission to Switzerland. Both our countries share a strong focus on innovation and high-quality solutions, making them excellent partners for collaboration in key areas such as biotechnology and semiconductors.

The Netherlands has long-standing trade relations with Switzerland. Today the Swiss rank as our tenth-largest trading partner. These ties continue to thrive, driven by our shared ambition for technological excellence and sustainable growth.

Biotechnology is a sector where Switzerland holds a world-leading position, with a high concentration of innovative companies and a strong research and development ecosystem. The Netherlands also has a robust biotech landscape, with cutting-edge expertise in areas such as cell and gene therapy, nuclear medicine, and close collaboration between science and industry. Together, we can explore new opportunities for innovation that deliver both economic and societal value.

Semiconductors represent another area of great potential for cooperation. The Netherlands is a global leader in semiconductor technology, from design and production to advanced innovation ecosystems. Switzerland complements this with expertise in specialized niches such as smart sensors and energy-efficient chip design. By joining forces, we can strengthen Europe's competitive edge and drive forward the technologies that will shape our future.

During this mission, we will bring together companies, knowledge institutions, and governments to deepen our partnerships and create new opportunities. With a program of company visits, interactive sessions, and networking events, we aim to foster lasting connections and mutual growth.

I look forward to working with you to make this mission a success. If you have any questions, please do not hesitate to contact me. I wish you all an inspiring and productive mission.

Ingrid Thijssen

President of the Confederation of Netherlands Industry and Employers VNO-NCW

Word of Welcome



Welcome to Switzerland!

The embassy is very pleased to welcome the – as far as our records go - largest ever economic mission from the Netherlands to Switzerland.

With its ecosystem rich in expertise, capital and research facilities, Switzerland is a very interesting – and often complementary – partner for the Netherlands. We both are highly innovative, internationally oriented, knowledge-intensive economies. There are many things we can do together and learn from each other. We face similar domestic challenges, such as an ageing population, with more demands on and rising costs of health care, and as open economies we are both affected by a global environment that is not exactly becoming more free trade friendly. In the current geopolitical context, it is crucial that we invest in the competitiveness of Europe. Together, Switzerland and the Netherlands can contribute to that. Together, we can create impactful innovative and sustainable solutions that are essential for our future welfare, wellbeing and prosperity.

When it comes to doing business, we are both pragmatic, averse to excessive hierarchy, and we both appreciate it when people do as they say and deliver on their promises. Maybe that is the reason the Swiss and the Dutch get along so well. Or maybe it is because of the long history we share, connected by the river Rhine.

Whatever the reason, as ambassador I am always positively surprised to see how much goodwill we have here. The doors for cooperation with the Netherlands are wide open. However, enter well prepared. Switzerland is not an EU country, the VAT rules differ, they speak four different languages, and there are 26 cantons with a great deal of autonomy and regulations of their own. Therefore, to be successful in Switzerland you must do some homework. And you must be willing to invest in the relationship with your local counterparts.


The team of the Netherlands embassy in Bern stands ready to support you both during the mission and afterwards. We look forward to a successful mission that will help create many connections for further collaboration!

Karin Mössenlechner

Ambassador of the Kingdom of the Netherlands to Switzerland

The Netherlands

The Netherlands



Locations

- 1. Amsterdam (and Airport Schiphol) |
- 2. Arnhem | 3. Assen | 4. Breda |
- 5. 's-Hertogenbosch | 6. Eindhoven |
- 7. Enschede | 8. Groningen | 9. Haarlem |
- 10. The Hague | 11. Leeuwarden |
- 12. Lelystad | 13. Maastricht |
- 14. Middelburg | 15. Rotterdam |
- 16. Utrecht | 17. Zwolle |

Introducing the Netherlands

How do the Dutch make a difference?

Through their interactive approach to finding innovative solutions to the big challenges facing the world today. The Dutch way of thinking and working has been shaped by centuries of living in the low-lying delta of the Netherlands.

Through the ages, the Dutch have joined forces to find ingenious ways to tackle challenges like water, urbanisation, energy, food, health and security. By being inventive, pragmatic and

open to new challenges, the Dutch have created a flourishing and resilient land.

The Netherlands is a constantly evolving ecosystem of cities, industry, agriculture and nature, all integrated through smart infrastructure. It is a source of knowledge and experience that the Dutch are keen to share with others. Learning from the past to create a better future. Together, seeking sustainable solutions for the most liveable world.



The Netherlands your partner in sustainable solutions

Worldwide rankings

1st

Largest flower exporter
(Source: OEC, 2022)

3rd

Largest exporter of
agricultural products
in the world
(Source: WUR/CBS, 2023)

4th

Largest importer of
goods in the world,
842.05 billion US
dollars
(Source: à Statista, 2023)

4th

Largest exporter of
goods in the world,
934.57 billion US
dollars
(Source: à Statista, 2023)

4th

Leading economy
worldwide by Foreign
Direct Investment
(FDI) inward stock,
2.86 trillion US dollars
(Source: à Statista, 2023)

6th

Greatest place to live
(Source: World Happiness
Report, 2024)

7th

on the Global
Innovation Index
(Source: WIPO, 2023)

9th

on the World
Competitiveness
Ranking
(Source: International
Institute for Management
Development, 2024)

Facts & figures

Official name:

Kingdom of the
Netherlands

Administrative structure:

The kingdom consists of four entities.
The Netherlands and three territories in the
Caribbean: Aruba and Curaçao and St. Maarten.

Capital:

Amsterdam

Special municipalities

The overseas islands of Bonaire, Saba and
St. Eustatius, all three of which are located in the
Caribbean.

Seat of government:

The Hague

Form of government

Parliamentary
democracy (cabinet
of Prime Minister and
Ministers) within a
constitutional
monarchy

Surface area

41,543 km²

Number of provinces:

12

Number of inhabitants (2024):

18 million

Number of inhabitants
per km² (2024):

533

Head of State:

His Majesty King
Willem-Alexander,
King of the
Netherlands,
Prince of Orange-
Nassau

Monetary Unit:

Euro

Languages:

Dutch, Frisian and on the
overseas islands also
English and Papiaments

Unemployment rate
(CBS, 2024):

3.7%

Location:

Western Europe
bordering Germany,
Belgium and the
North Sea

GDP per capita

(World Bank, 2024):

57,800 US dollars

English speaking Dutch
people:

90%

Switzerland and the Netherlands:

Switzerland and the Netherlands: advancing together in health and high-tech


Switzerland and the Netherlands are both highly innovative and outward-looking economies, with strong research landscapes and a shared commitment to practical innovation. These common traits have laid the foundation for a long-standing and constructive partnership. As advanced knowledge economies, we both value collaboration that delivers real-world impact. Our shared location along the Rhine has supported trade, while similar business cultures have helped build lasting relationships.

Switzerland and the Netherlands are recognised leaders in biotechnology and high-tech semiconductors. Both countries are investing in technologies that improve lives and support

sustainable development. With this mission, we aim to strengthen our partnership by connecting governments, businesses and knowledge institutions across borders. Together, we are building bridges between two of Europe's most advanced ecosystems.

Biotechnology: driving health innovation together

Switzerland is recognised as a global leader in life sciences, combining world-class research with an innovative industrial sector that spans biotechnology, pharmaceuticals, and medical technology. The Netherlands is a key European player in medtech and biotech, with particular expertise in regenerative medicine, diagnostics



and personalised health. As Europe faces an ageing population, increasing health demands, and the need for more sustainable healthcare, Swiss and Dutch institutions are well-positioned to collaborate on smart, scalable and patient-focused solutions. From joint research to clinical innovation, both countries see biotechnology as a driver of global health progress.

Hightech semiconductors: enabling the digital transition



Semiconductors are the foundation of digital innovation. From AI to mobility and clean energy, they power the technologies that shape our economies and societies. Switzerland is known for its precision engineering and microelectronics expertise. The Netherlands, with its dense value chain and global players such as ASML and NXP, plays a leading role in Europe's chip production capacity. Both countries are investing in the resilience and sustainability of semiconductor supply chains. Through this mission, the Netherlands aims to explore opportunities for Swiss and Dutch cooperation in research, advanced manufacturing and talent development, with a focus on long-term value creation.

Innovation through collaboration

The Netherlands and Switzerland share a strong belief in open innovation and international collaboration. In both countries, partnerships across government, business, academia and society are essential for turning ideas into real-world impact. This mission builds on that approach by bringing together partners with complementary strengths. It supports a shared ambition to drive sustainable growth, improve health outcomes and strengthen Europe's position in key technologies.

Towards a future-focused partnership

In a rapidly changing world, global cooperation is more important than ever. The Netherlands sees Switzerland as a like-minded partner with a shared commitment to excellence, innovation and sustainable development. This economic mission marks another step in deepening our relationship and exploring new opportunities for long-term success.



Sources: RJ Fotografie & Bart van Overbeek

Biotechnology



Peter Timmerman

Head of Peptide Science

+31 6 5184 1878

peter.timmerman@biosynth.com



Sangram Kale

Head of Peptide Discovery and

Epitope Mapping

+31 6 4485 7481

sangram.kale@biosynth.com

Online information

[LinkedIn Peter Timmerman](#)

[LinkedIn Sangram Kale](#)

Biosynth

Where chemistry meets biology, products meet services and innovation meets quality, Biosynth secures life science supply chains with manufacture and supply of high quality products. With an unrivalled research product portfolio of over one million products and end-to-end manufacturing services, we are science led and customer focused to solve problems, taking pride in delivering products and projects that others cannot. Our expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner.

Supplying the pharmaceutical, life science and diagnostic sectors, along with customers across food, agrochemistry and cosmetics, we have facilities across three continents and a rapid global distribution network. We produce chemicals on the milligram to ton scale, and at ISO 9001 and GMP, with peptides at mg to multikilogram scale.

Biosynth

Zuidersluisweg 2

8243 RC Lelystad

The Netherlands

<https://www.biosynth.com/timeline>



Sharita Doerga

Manager Partnerships & Alliances
+31 6 8312 5587
sharita.doerga@biotechbooster.nl

Biotech Booster

Biotech Booster is a national program funded by the Dutch National Growth Fund that supports the commercialization of biotechnology findings in The Netherlands. Biotech Booster offers financial support, mentorship and networking opportunities to guide scientists and entrepreneurs from the idea stage to an investable or commercial proposition.

The goal is to make sure that the benefits of biotechnology will have more and faster impact on society. Moreover, Biotech Booster facilitates close collaborations between public and private partners in the biotechnology sector and established five Thematic Clusters following biotechnological focus areas: White: Industrial Biotechnology & Production (TC 1); Green: Agriculture & Food (TC 2); Red: ATMP's, Biopharmaceuticals & Associated Enabling Technologies (TC 3); Red: Diagnostics and Services (TC 4); and Red: Vaccines, Small Molecules, Discovery & Development Platforms (TC 5).

- Since its inception, Biotech Booster has grown significantly, with a total of 71 projects as part of their program. These projects all have an end goal of creating positive societal impact through their invention.
- Biotech Booster partners with universities from all over the Netherlands, and Impact and Business developers support the projects personally throughout their journey.
- What makes Biotech Booster unique is that they do not only give financial resources, but they also provide support, and want to build a community of people that want to make biotechnology work.

Online information

[LinkedIn Biotech Booster](#)

[Youtube Biotech Booster](#)

[LinkedIn Sharita Doerga](#)

Biotech Booster

Jaarbeursplein 6
3521 AL Utrecht
The Netherlands
<https://www.biotechbooster.nl/>



Bas-Jan Hoogenberg

Director

+31 6 1518 7083

bas-jan.hoogenberg@bondus.nl

Bondus

At Bondus, we specialize in bonding technologies for microfluidics, lab-on-chip and bonded manifolds. We offer contract manufacturing, from iterative prototyping up to volume manufacturing. Bondus manufacturers mainly for customers that are active in the IVD market and for lab consumables that include microfluidics. Example products include blood analysis devices, microfluidic reactors for medicine manufacturing and organ-on-chip consumables.

Bondus employs proprietary bonding technologies for polymer microfluidics, as well as material combinations with glass or silicon substrates. These allow for the creation of highly integrated devices and cost optimizations. Further functionalization can be added, such as valves, electrodes or biomarkers.

Our diverse and motivated team is dedicated to bringing your product to life. The high level of automation allows for repeatable manufacturing right from the start of prototyping as well as scalable manufacturing up to high volume production.

What will you build?

Online information

[LinkedIn Bondus](#)

Bondus

Ceintuurbaan 15

8022 AW Zwolle

The Netherlands

<https://www.bondus.nl>



Carlo Alberto Paggi

Managing Director
+31 6 4114 3458
carlo@chnr.co



Dustin Dopsa

Managing Director
+49 172 385 0016
dustin@chnr.co

Online information

[LinkedIn chiron](#)

Chiron

Gaetano Martinolaan 63A, 63 – 65
6229 GS Maastricht
The Netherlands
<http://www.chnr.co/>

chiron

- Advanced In-vitro Technologies
- Derisking Clinical Trials
- Organ on Chip

chiron is an advanced in-vitro technologies company, and organ-on-chip (OoC) pioneer, delivering human-relevant data early in drug development, reducing costs, accelerating timelines, and lowering the risk of late-stage clinical failures.

The company is currently focusing on high-value applications within the indications of arthritis (osteoarthritis, rheumatoid arthritis) and oncology, leveraged upon its proprietary active mechanical stimulation technology and organoid platforms. chiron generates invaluable knowhow for its clients (pharma, biotechs, and the like) with a service-based business model, and bespoke approach for the custom requirements of each client.

chiron is striving to push the boundaries of recapitulating human physiology in vitro, in order to develop a better understanding of disease mechanisms, reduce the risk of late-stage clinical failures, and provide improved patient outcomes.

Demcon

Partner in product development

Demcon life science & health provides contract engineering and manufacturing services in medical technology, biotechnology, and in-vitro diagnostics.

Our portfolio encompasses diagnostic and monitoring systems, advanced treatment equipment, and critical care systems, covering the entire development process from concept to production.

Catering to both startups and OEMs, we focus on accelerating the time-to-market for high-quality, patient-centered innovations. With 30+ years of experience and a proven project portfolio, we efficiently integrate existing knowledge with new insights, streamlining development without compromising quality.

All solutions adhere to rigorous standards, including ISO 9001, ISO 13485, CE-MDR, CE-IVDR, FDA, and GMP.

**Daniel Tan**

Managing Director

+31 6 5088 0479

daniel.tan@demcon.nl

Online information[LinkedIn Demcon Life Sciences & Health](#)[Website Biotech](#)**Demcon**

Delftechpark 23

2628 XJ Delft

The Netherlands

<https://lifescienceshealth.demcon.com/>



Monique van Scherpenzeel

CEO & Founder

+31 6 1722 2261

monique.vanscherpenzeel@glyco
mscan.com



Mischa Vreeburg

CTO

+31 6 2122 5680

mischa.vreeburg@glycomscan.com

Online information

[LinkedIn GlycoMScan](#)

GlycoMScan

Snelliusweg 75

6827 DG Arnhem

The Netherlands

<https://www.glycomscan.com/>

GlycoMScan

GlycoMScan B.V. was founded in 2018 by Monique van Scherpenzeel, PhD who switched her career from academia into a service company. She has experience in mass spectrometry and developed analytical methods for clinical diagnostics, with an expertise on protein glycosylation through studying patients with Congenital Disorders of Glycosylation. As postdoctoral fellow at the ETH in Zürich a nucleotide sugar analysis method was developed, based on their method to study central carbon metabolism.

We serve national and international pharma and biotech companies with pharmacokinetics and analyses to characterize novel drug candidates, e.g. antibody-drug conjugates. As Eurostar we were involved in development of well-defined cell culture media to drive protein glycosylation, and developed the GLYSEC platform to analyze cell-surface glycosylation. Both are of high need in the field of immune-oncology to assist in finding new drug targets, as well as to improve drug potency and specificity.

I am impressed by the scientific quality of the Swiss scientists and therefore I love to work with them. We already collaborate for years with EPFL in Lausanne, Asterivir and Orpha Labs. It is our pleasure to grow our network in Switzerland to further strengthen our company.



Bart Smeets

Associate Professor / Lecturer-
Researcher

+31 6 2144 9993

bart.smeets@radboudumc.nl

HAN University of Applied Sciences

HAN University of Applied Sciences is a leading Dutch knowledge institution that combines education with practice-based research. Through its Centre of Expertise, the ****BioCentre****, HAN focuses on applied life sciences, developing innovative solutions in health, biotech, and drug discovery. By working closely with industry, HAN drives regional and international innovation while preparing students and professionals with the skills needed for tomorrow's challenges.

Online information

[Website HAN Drug Discovery](#)

[LinkedIn Bart Smeets](#)

HAN University of Applied Sciences

Laan van Scheut 2

6526 EM Nijmegen

The Netherlands

<https://www.han.nl/>



Laura Windt

Project Lead Organ-on-Chip
+31 6 1497 0282
windt@health-holland.com



Laura Duran

International Relations Manager
+31 6 2853 2689
duran@health-holland.com

Online information

[LinkedIn Health Holland](#)

[Health Holland Brochure](#)

[Website OoC Project](#)

Health~Holland

Wilhelmina van Pruysenweg 104
2595 AN The Hague
The Netherlands
<https://www.health-holland.com/>

Health~Holland

Top Sector Life Sciences & Health (Health~Holland) is the driving force behind innovation within the Dutch Life Sciences & Health (LSH) sector. We strive to achieve both economic and societal impact.

We leverage the power of (inter)national public-private partnerships and collaborative efforts to stimulate groundbreaking scientific discoveries, accelerate technological innovations and address societal challenges, helping to transform health and care. We do this on behalf of the Netherlands and enable this through our financing and connecting role.

We engage in a range of international collaborations. A notable example is our strategic collaboration with Switzerland focused on organ-on-a-chip technology.



Wim Altena

Director Customized Solutions
+31 6 8243 0519
sales@ims-nl.com

IMS - Production Automation

As products become ever-more intelligent, manufacturers need to adopt high-tech production technology to achieve world-class product quality on an economical scale. This is the world of IMS. We are a smart and forward-thinking machine manufacturer in the high-end precision industry, providing innovative solutions in high-precision production—from low to high volumes, from prototyping to mass production.

If you are looking for the highest quality and most efficient automated production machines, at IMS we have over 25 years of experience in the field of high-precision medical solutions. We assist various organizations with their questions on assembling pacemakers, medical screws, needle arrays, blood testers and much more. We are always eager to solve your medical challenge, together with you. We offer automation solutions to any high precision question you may have.

Online information

[LinkedIn Wim Altena](#)

[YouTube IMS](#)

IMS - Production Automation

Einsteinstraat 14-16
7601 PR Almelo
The Netherlands
<https://ims-nl.com/>

**Esther Peters**

Director

+31 6 4611 1505

epeters@leidenbiosciencepark.nl**Amy Anderson**

Business Developer

+31 6 1745 7134

aanderson@leidenbiosciencepark.nl

Leiden Bio Science Park (LBSP) is the Netherlands' largest Life Sciences and Health cluster and one of Europe's most vibrant innovation hubs. With over 500 organisations, 26,000 professionals, and 27,000 students, the park is a powerhouse of talent, research, and entrepreneurship.

From the inception, the park was intended to be a place for cross-cutting synergy amongst different organizations. Today, Leiden Bio Science Park is home to world-class universities, and academic hospitals, a mix of start-ups, scale-ups, and global Life Science companies and public institutions. Together, these actors collaborate across disciplines, accelerating innovation through proximity and partnership.

The park's fully integrated value chain is unique with every stage of the innovation cycle: from fundamental research and education, clinical and translational development, to manufacturing and commercialisation. LBSP's ecosystem is geared toward tackling global health challenges across key focus areas: Cell/Gene Therapy, Vaccines and Infectious Disease, Diagnostics and Technical Innovation, Prevention and Lifestyle – just to name a few.

In essence, we are positioned strategically as a gateway to Europe and therefore sees the true value in deepening ties with international partners and innovation hubs worldwide. As we expand global collaborations, we welcome joint initiatives that further advance health innovation across borders.

Online information[LinkedIn Leiden Bio Science Park](#)**Leiden Bio Science Park**

Galileiweg 8

2333 BD Leiden

The Netherlands

<https://leidenbiosciencepark.nl>



Luo Automation

At Luo Automation, we are dedicated to providing innovative solutions to improve the visual inspection process of our pharmaceutical clients. Our team specializes in delivering high-quality machines that enhance business performance and drive quality.



Joren van der Horst

CEO

+31 6 2671 5133

jvanderhorst@luoautomation.com

Online information

[LinkedIn Luo Automation](#)

Luo Automation

Molengraaffsingel 12

2629 JD Delft

The Netherlands

<https://luoautomation.com>

MIMETAS

Every great therapy starts with a deep understanding of disease processes. We capture human physiology with unmatched accuracy and at scale in our Organ-on-a-Chip platform. This unlocks insights that traditional models can't deliver, helping you develop the next generation of medicines.



Paul Vulto

CEO

+31 6 3901 2316

p.vulto@mimetas.com

Online information

[LinkedIn Paul Vulto](#)

MIMETAS

De Limes 7

2342 DH Oegstgeest

The Netherlands

<https://www.mimetas.com>



Jan Hunik

CEO

+31 6 5156 9976

jan.hunik@mosamatrix.com

MosaMatrix

3D printing revolutionizes human cell culturing and tissue regeneration. Bioinks are gel-forming materials that create the extracellular matrix for the cells to grow new tissue. Current bioinks have many drawbacks and MosaMatrix has developed a new class of bioinks for 2D/3D printing of living cells. The MosaMatrix bioinks show excellent printability, high cell survival and good tissue maturation. The MosaMatrix bioinks are unique in the adjustment of biomechanical properties like elasticity and stiffness. Our bioinks are easy to handle, allow the addition of peptide fragments, are fully transparent and non-animal derived.

Our first product is Naturematrix supported by successful user data, e.g. in cartilage and kidney cell-lines.

Naturematrix can be used in most commercially available bioprinters, based on extrusion. There is no UV curing needed. Naturematrix consists of an oxidized alginate back-bone polymer and mix of two non-toxic cross-linking molecules to create a wide range of biomechanical properties.

MosaMatrix is seeking collaborations with drug-discovery laboratories to develop and demonstrate the use of Naturematrix for a wide variety of 2D/3D printed cell-lines.

Online information

[LinkedIn MosaMatrix](#)

MosaMatrix

Oxfordlaan 55

6229 EV Maastricht

The Netherlands



Sophia Kolbe

Business Developer

+31 6 2181 1463

s.kolbe@necstgen.com

NecstGen

Cell and Gene Therapies have great potential to treat and cure some of the world's most devastating diseases. Due to their complexities, this new generation of therapies faces challenges to reach patients including access to knowledge and facilities.

NecstGen is a non-profit CDMO and centre of excellence for Cell and Gene Therapy, located in a purpose-built GMP facility on the largest bio-cluster in the Netherlands, Leiden Bio Science Park. Here, NecstGen provides critical contract development, manufacturing and rental services to academic and industrial therapy developers. Successful completion of such services helps to accelerate the delivery a new generation of therapies to patients.

Products & Services offered

Manufacturing

- Full contract manufacturing services by expert teams for Cell Therapy and Viral Vector,
- Pre-clinical, clinical-grade material,
- Cleanroom rental including services for QC, QA, and QP,
- Hybrid support on a flexible basis where our team complements yours.

Development

- Process design, scale-up, optimisation and automation for Cell Therapy and Viral Vector,
- Assay development for in-process controls, release- and potency tests,
- Technology transfer in and out with flexibility in-mind for the future progress of your manufacturing,
- Consultancy-based work to advise on decision making.

Online information

[LinkedIn NecstGen](#)

NecstGen

Sylviusweg 62

2333 BE Leiden

The Netherlands

<https://necstgen.com/>

**Jan Güse**

Head Public Affairs Netherlands
+31 6 5354 4008
jan.guse@novartis.com

Novartis Pharma

Novartis is an innovative pharmaceutical company committed to making a meaningful contribution to healthcare. By leveraging science-based innovations, we strive to achieve better treatment outcomes for patients around the world. In our search for new medicines, we are consistently among the world's top companies, investing in research and development. Worldwide, Novartis' products reach nearly 1 billion people.

We have a clear focus on core therapeutic areas (oncology, immunology, neuroscience and cardiovascular, renal and metabolic), with multiple significant in-market and pipeline assets in each of these areas, that address high disease burden and have substantial growth potential. In addition to two established technology platforms (chemistry and biotherapeutics), three emerging platforms (gene & cell therapy, radioligand therapy, and xRNA) are being prioritized for continued investment into new R&D capabilities and manufacturing scale.

Our strategy is to deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. We dedicate ourselves every day with enthusiasm and passion to our mission: to reimagine medicine to improve and extend people's lives.

Novartis Pharma

Haaksbergweg 16
1101 BX Amsterdam
The Netherlands
<https://www.novartis.com>



Ingrid Relou

Programme Manager

+31 6 3645 0309

ingrid.relou@nxtgenhightech.nl



Sabine Middendorp

Project Leader

+31 6 1806 6833

s.middendorp@hdmt.technology

Online information

[LinkedIn NXTGEN Hightech](#)

NXTGEN Hightech

Hightech Campus 32

5656 AE Eindhoven

The Netherlands

<https://nxtgenhightech.nl/en/biomed/>

NXTGEN Hightech

NXTGEN Hightech is a National Growth Fund program aimed at driving the development of next-generation high-tech equipment in the Netherlands. With 330 partners, including more than 300 companies, and investments exceeding €1 billion, NXTGEN Hightech is one of the largest high-tech innovation programs in the Netherlands. The program's ambition is to generate an additional €6 to €9 billion in economic growth by 2040 by creating new high-tech businesses that simultaneously solve future challenges. Focus areas include semiconductors, energy, agri-food, laser satellite communication, composite production technology, and biomedical production technology. The program is based on key enabling technologies in which the Netherlands excels, such as optomechatronics, thin-film technology, and bionanotechnology.

Biomedical Production Technology

Biomedical Production Technology stands out as one of the six focus areas of NXTGEN Hightech. It brings together the latest scientific advancements with industry practices to develop next-generation medical devices. It focuses on converting cutting-edge expertise in lab-on-chip, organ-on-chip, artificial organs, and cell production technology into systems that are scalable and ready for the market.

The Biomedical Production Technology domain includes over 60 public and private partners from various sections such as high-tech, microtechnology, biology, clinical practice and regulation. With these partners, we bridge the gap between fundamental research and industrial-scale manufacturing, with an emphasis on regulatory alignment and system standardization. This approach speeds up the development of medical technologies that are accurate, scalable, and relevant to clinical needs.

Additionally, we are working on a collaborative platform designed to speed up the development of biomedical technologies. This platform will offer a shared production infrastructure where developers, suppliers, and end users can access generic equipment and standardized, qualified processes, all from a single (virtual) hub.

By doing this, NXTGEN Hightech's Biomedical Production Technology domain is not just enhancing the creation of smarter, more personalized healthcare solutions, it is also streamlining the path from prototype to finished product. This will reinforce the Netherlands' position as a leader in the high-tech biomedical manufacturing sector.



Daniela Salvatori

Scientific Director
d.salvatori@uu.nl

Ombion Centre For Animal-Free Biomedical Translation

The translation of biomedical knowledge to patients and users results in new medicines, medical technologies, and food products. This benefits our health, our environment, and economy. Animal testing is currently an important link in the biomedical development process, but it is increasingly under pressure. Often, animal tests are not a good model for human application; they are time-consuming, expensive, and cause animal suffering. To continue improving the health of humans and animals, a radically different approach is needed: making the step to humans and animals faster and more effective, without relying on animal testing by default.

**Ombion Centre For Animal-Free Biomedical
Translation**

Yalelaan 62

3584 CM Utrecht

The Netherlands

<https://site.ombion-cpbt.nl/>



Arnoud Huisman

CEO and Chairman of the Board
+31 6 3048 4637
arnoud.huisman@oncodeaccelerator.nl



Jetta Bijlsma

Director of Program Management
+31 6 8311 7210
jetta.bijlsma@oncodeaccelerator.nl

Online information

[LinkedIn Oncode Accelerator](#)
[Video Oncode Accelerator](#)
[Video Explainer Animation](#)

Oncode Accelerator

Jaarbeursplein 6
3521 AL Utrecht
The Netherlands
<https://www.oncodeaccelerator.nl>

Oncode Accelerator

Oncode Accelerator is a public-private partnership that is funded by the Dutch National Growth Fund (NGF), which aims to innovate and accelerate the development of new cancer therapies by placing cancer patients at the core of preclinical therapy development. It is a collaboration between six coordinating partners: Leiden University, Leiden University Medical Center, the Netherlands Cancer Institute, Princess Máxima Center, UMC Utrecht and the Oncode Accelerator Foundation.

Together, we believe preclinical drug discovery and therapy development can be accelerated and de-risked using an innovative combination of well-defined patient cohorts, organoid models, and artificial intelligence platforms. To make optimal use of our preclinical development infrastructure, we utilize four preclinical development pipelines, so called workstreams, representing the development of the four most prominent types of cancer therapies:

- small molecules
- biologics
- cell and gene therapy
- therapeutic vaccines

Oncode Accelerator co-funds preclinical oncology drug discovery and development projects that:

- further develop a validated target or hit,
- use one or more of our innovation platforms: well-defined patient cohorts, organoid models and/or AI, and
- develop a therapeutic vaccine, biologic, small molecule or cell & gene therapy

We are actively looking for new partners to join our community, collaborate, and demonstrate that together, we can deliver more effective, personalized cancer treatments faster.

We invite prospective partners to submit an application for a “Demonstrator Project”. Demonstrator Project partners gain access to our unique network and infrastructure, streamlining their collaboration with world-class research institutes and industry, and the top scientists and state-of-the-art technologies therein. In addition, granting of a Demonstrator Project includes a dedicated team to help manage your development project from start to finish, and co-funding of up to 50% of the total project budget.



Guido Zaman

Managing Director

+31 6 5512 1711

guido.zaman@oncolines.com

Oncolines

Oncolines B.V., a subsidiary of Symeres Netherlands B.V., is a precision medicine services company in oncology, immunology and cancer immunotherapy. Our Clients are clinical and preclinical biopharma companies and academic institutions that seek differentiation for their drugs and drug candidates. By cancer cell panel profiling, we identify predictive drug response biomarkers, new disease indications and synergistic drug combinations. We present results in a unique interactive reporting format to facilitate easier and faster interpretation of results.

To investigate the mechanism of action of compounds, we perform gene and protein expression analysis, DNA and RNA sequencing. We generate, process, analyze, visualize, and interpret complex data. We present meaningful data and discuss them with our Clients. With our extensive reference compound database we identify differentiation and mechanism of action. We share our knowledge in cancer drug development. We help cancer researchers to move their projects to the clinic faster.

Online information

[LinkedIn Oncolines](#)

Oncolines

Kloosterstraat 9

5349 AB Oss

The Netherlands

<https://www.oncolines.com/>



Albert Konijnenberg

Product Director

+31 6 4327 8986

albert.konijnenberg@optics11life.com



Lieke van der Leegte

Sales Director

+31 6 5279 2052

lieke.vanderleegte@optics11life.com

Optics11Life

Optics11 Life is transforming drug development and regenerative medicine by leveraging its unique fibre-optic sensing technology, with a core focus on mechanobiology. The company's instruments address the high failure rates in drug development by providing precise measurements of cell and tissue mechanics, crucial for understanding disease progression and therapeutic efficacy.

Optics11 Life's proprietary technology facilitates high-throughput, sensitive measurements compatible with advanced 3D in-vitro models, such as organoids and organ-on-chips, which better replicate human physiology. The company's nano-indentation product portfolio, encompassing the Pavone, Piuma, and Chiaro systems, supports preclinical drug development, regenerative medicine, and biomaterials research. These instruments enable researchers to measure mechanical properties under near-physiological conditions, yielding valuable insights into diseases like fibrosis, cancer, and neuromuscular disorders.

The recently introduced Cuore system provides a 3D contraction force platform, providing a precise functional readout for engineered muscle bundles for both skeletal and cardiac muscle tissue. Cuore revolutionizes 3D tissue culture for therapy development in heart failure, neuromuscular, and metabolic diseases as it allows the production and analysis of advanced in vitro-systems to model biology, disease, and drug response of contractile tissues. It is a pillar-based system for real-time recording and continuous stimulation of contractile activity of engineered tissues.

Online information

[LinkedIn Optics11 Life](#)

[On-chip mechanical characterization](#)

[Pavone nano-indentation platform](#)

Optics11Life

Hogehilweg 1

1101 CA Amsterdam

The Netherlands

<https://www.optics11life.com/>



Wenliang Dong

CEO

+31 6 4820 2369

wen.dong@orca-therapeutics.com

Online information

[LinkedIn Wenliang Dong](#)

ORCA Therapeutics (Headquarters)

Onderwijsboulevard 225

5223 DE 's-Hertogenbosch

The Netherlands

<https://www.orca-therapeutics.nl/>

ORCA Therapeutics

Transformative Neo-Adjuvant Cancer Immune Activator

Breakthrough Clinical Results

ORCA-010 represents the first oncolytic immunotherapy to achieve 100% immune activation across all treated patients. In Phase I/IIA prostate cancer (mid/high risk early stage PCa) trials, high-dose cohorts demonstrated:

- 50% durable PSA decrease in localized disease patients
- 33% cancer-free biopsies at one-year follow-up
- Excellent safety profile with only transient Grade I-II adverse events

Superior Technology Platform

10-100x more potent than competing oncolytic viruses achieving improved tumor cell killing potency across multiple cancer types. The optimized viral design delivers enhanced cancer cell kill and tumor microenvironment disruption.

Strategic Market Position

First-in-class immune activation creates unique positioning for combination therapies with checkpoint inhibitors, in immunologically cold tumors.

Diversified Clinical Pipeline

Robust development program spanning discovery through clinical stages across high-value indications: prostate cancer (Phase I/IIA completed), glioblastoma (funded collaboration), esophageal cancer, pancreatic cancer and metastatic prostate cancer.

Highlights for Partners

- Validated clinical efficacy accelerates partnership timelines and reduces regulatory risk
- Multiple indication potential maximizes ROI across diverse cancer types
- Proven immune activation enables and broadens clinical target and combination therapy opportunities
- Established safety profile supports rapid clinical scaling



Protyon

Protyon is a med tech startup from the Netherlands. We aim to accelerate cancer therapy effectiveness by guiding clinicians, personalizing therapy, and enhancing lives. Our software uses 3D digital models to provide a best therapy match for lung cancer patients.



Rositsa Jordanova

CEO & Founder

+31 6 2111 3935

rjordanova@protyon.tech

Online information

[LinkedIn Rositsa Jordanova](#)

[LinkedIn Protyon](#)

Protyon

Winschoterdiep 50

9723 AB Groningen

The Netherlands

<https://protyon.tech/>

Provincie Noord-Brabant



Iris Schoones

Policy Advisor International Affairs
+31 6 5279 4586
ischoones@brabant.nl

Province of Noord-Brabant

Brabant is a prime location in the Netherlands, offering rapid and direct access to key markets in Europe and the rest of the world. Our location drives innovation, and innovation drives our location. A profound legacy of innovative excellence was laid down by the global multinational Philips and continues to permeate the region today across various dynamic industry sectors, working together, collaborating, and co-creating solutions for the great challenges of our times.

Life Sciences & Health

Brabant holds a strong position in the Netherlands when it comes to the Life Sciences & Health industry. The presence of the full value chain in the field of Medtech and Pharma shows that Brabant has a mature and thriving LS&H industry. There are 910 Life Sciences & Health companies in Brabant, employing 18,160 people – 15.6% of all Dutch Life Sciences & Health companies and 23.5% of Dutch industry employees. This means that Brabant accounts for a large proportion of all Dutch life sciences jobs. The majority of these companies are involved in wholesale, followed by medtech. Although pharmaceutical companies only represent 4% of companies in the industry, they account for 33% of jobs. The pharmaceutical industry is made up of relatively large companies in employment terms (on average 150 jobs per company), while the companies in the other branches are relatively small (10-14 jobs per company).

Important and interesting names in Noord-Brabant within the LSH sector are: Thermo Fisher Scientific, MSD Pharmaceutical Operations, MSD Biologicals and MSD Animal Health, Ardena, Aspen, Amgen, Philips Healthcare, VDL ETG (Enabling Technology Group), IDB Holland B.V. by Novartis and BioConnection.

Online information

[LinkedIn Iris Schoones](#)

Province of Noord-Brabant

Brabantlaan 1
5216 TV 's-Hertogenbosch
The Netherlands
<https://www.brabantisbright.nl>



Nick Beijer

Business Development
+31 6 4114 4499
n.beijer@regmedxb.com

RegMed XB: Regenerative Medicine Crossing Borders

RegMed XB is a translational platform that currently comprises Dutch and Flemish public (universities and governments) and private (health foundations and companies) partners that aims to develop regenerative medicine (RM) solutions for patients in order to cure chronic diseases and reduce healthcare expenses. RegMed XB builds a strong RM ecosystem in which science leads to innovative products and new economic activity. The closely knitted RM ecosystem facilitates easy interactions between scientists, universities and companies, and with the 56 million investment in the National Pilot Factory for Regenerative Medicine, RegMed XB partners and the Dutch National Growth Fund underscore the importance of solidifying the RM ecosystem further by creating an attractive environment to start new RM initiatives, collaborations and businesses.

RegMed XB has a strong interest in collaborating internationally to shorten the time to market for regenerative therapies and improve availability of these products.

Products & Services offered

- Research Excellence: joint research by excellent researchers in Moonshot Projects (Diabetes, Eye/cornea diseases, Kidney, Cardiovascular and Osteoarthritis)
- Business Development & acceleration: accelerated valorization of promising research results
- Public-Private Entrepreneurship: targeted collaboration between companies and knowledge institutions
- Seed Capital: funding for early commercial development of research results
- Infrastructure: shared infrastructure and technology platforms for development and production (Pilot Factory)

Online information

[LinkedIn RegMed XB](#)

[Video RegMed XB](#)

RegMed XB

Minderbroedersberg 4-6
6211 LK Maastricht
The Netherlands
<http://regmedxb.com>



Tjerk Balk

Lead, Government & Public Affairs
+31 6 4561 7082
tjerk.balk@roche.com

Roche

Roche is a Swiss multinational healthcare company with a 125-year history of pioneering scientific innovation from our global headquarters in Basel. With a unique combination of Pharmaceuticals and Diagnostics, we are a world leader in personalized healthcare. Our mission is to do now what patients need next by developing transformative solutions for areas of high unmet medical need, such as oncology, immunology, and neuroscience.

We are deeply committed to Research and Development, investing billions annually to push the boundaries of medical science. We believe that groundbreaking innovation doesn't happen in a vacuum. It requires a collaborative ecosystem where different partners — from academia and startups to large corporations — bring their unique expertise to the table. This is why technology partnering is so important to us.

We are all interconnected. As an ecosystem, we rely on each other to translate scientific discovery into tangible patient benefits. For this system to truly prosper, innovation must be valued and its development supported by a willingness to invest in new solutions that benefit society. We look forward to connecting with the Dutch innovation ecosystem and exploring how we can partner to shape the future of healthcare.

Online information

[LinkedIn Tjerk Balk](#)

Roche

Beneluxlaan 2a
3446 GR Woerden
The Netherlands
<https://www.roche.com/>



Judith Vivie

Co-Founder & COO

+31 6 4843 3777

j.vivie@scddiscoveries.com



Till Olfers

Senior Business Development
Manager

+49 17 0746 0908

t.olfers@scddiscoveries.com

Online information

[LinkedIn Judith Vivie](#)

Single Cell Discoveries

Varrolaan 100

3584 BW Utrecht

The Netherlands


<https://www.scddiscoveries.com/>

Single Cell Discoveries

Single Cell Discoveries (SCD) is a CRO for single-cell, bulk and spatial transcriptomics services. SCD spun off from one of the first core facilities for single-cell sequencing in the world and consists of a team of transcriptomics experts in the field. We are dedicated to deliver high-quality data to clients worldwide and offer a suite of unique technologies. We offer end-to-end support, from project design to data analysis. SCD also develops its own methods and can cover biological questions usually out of reach using standard methodology.

SYNC BIOSYSTEMS

Part of the Demcon group



Berend van Meer

Co-Founder & Managing Director

+31 6 1496 4537

berend.van.meer@demcon.com

Sync Biosystems

Sync Biosystems develops an operator-independent and pipette-free refreshment system for standard wells plates to increase reproducibility. Based on patented technology, refreshments of medium outperform pipettes in terms of cell impact. Especially sensitive cell cultures such as suspension cells, organoids and hiPSCs can be handled without operator variations. In addition, this allows operators to subject their cell culture to kinetics of reagents or drugs.

Recognizing challenges in reproducibility of advanced cell cultures from own experience, the team at Sync Biosystems designs solutions that are compatible with the existing workflow and infrastructure. Being part of the Demcon group, Sync Biosystems is a startup with access to state-of-the-art engineering expertise and facilities.

Online information

[LinkedIn Berend van Meer](#)


Sync Biosystems

Galileiweg 8

2333 BD Leiden

The Netherlands

<https://syncbiosystems.com/>



Mikhail Langovoy

CEO

+31 4 0848 5245

langovoy@aitetractys.com



Bill To

CCO

bill.to@aitetractys.com

Online information

[LinkedIn Tetractys](#)

Tetractys

Het Eeuwse 57

5612 AS Eindhoven

The Netherlands

www.aitetractys.com

Tetractys

Tetractys is an international deep tech spin-off of two Universities, creating new generation of Graph AI that manages microbiological systems, in order to improve efficiency and safety in biomanufacturing and regenerative medicine.

We have our own technology stack in AI, with 18 years of development at top universities worldwide, and 5 years of data and experiments with commercial pharmaceutical factories.

Our AI system has been developed and trained to deal with the complexities of growth and production with microbial colonies and living cells, and has components that can improve observation of production processes, and can optimize production in live cycles, including not only process parameters, but also strategies for feeding, oxygenation and antibiotics use.

The system is already pre-trained, requires no investment in AI training, data, or hardware, and can start to bring value from day one.



Hans Schikan

Top Team Life Sciences & Health
+31 6 1432 6768
hans.schikan@gmail.com

Topsector Life Sciences Health (Health~Holland)

Under the leadership of the Top Sector Life Sciences & Health (Health~Holland), public and private parties are bundling their investments and activities nationwide to achieve economic and social impact for Health & Care, one of the four challenges of the Mission-driven Top Sectors and Innovation Policy of the Dutch government. The joint focus of the parties is formed by six Health & Care missions as formulated by the Ministry of Health, Welfare and Sport (VWS).

The central mission is as follows: In 2040, all people in the Netherlands will live in good health for at least five years longer, and the health differences between the lowest and highest socio-economic groups will have decreased by 30%. There are five underlying missions that contribute to this central mission through changes in lifestyle and living environment, offering more care in the right place and better prospects for people with a chronic illness, lifelong disability and dementia, and better protection against health threats. In addition, we support the economic opportunities within this social theme.

Online information

[LinkedIn Hans Schikan](#)

Topsector Life Sciences Health (Health~Holland)

Wilhelmina van Pruizenweg 104
2595 AN The Hague
The Netherlands
<https://www.health-holland.com/>



UMC Utrecht



Jeroen Vollenbroek

Assistant Professor

+31 6 1485 1388

j.c.vollenbroek@umcutrecht.nl

Online information

[Linkedin Jeroen Vollenbroek](#)

[LinkedIn Artificial Kidney](#)

[Innovation Lab](#)

University Medical Center Utrecht

Heidelberglaan 100

3584 CX Utrecht

The Netherlands

<https://artkidneylab.com/>

University Medical Center Utrecht | Artificial Kidney Innovation Lab

Research aim

We develop novel artificial kidney technologies to improve autonomy and quality of life of patients with kidney failure. We have developed a testing facility to fast-track the development of artificial kidney innovations from bench to bedside.

About us

We are a research group based at the University Medical Center Utrecht (UMC Utrecht), within the Department of Nephrology. Our research focuses on implantable artificial kidney technologies, dialysis innovations, and green nephrology.

We see a world where dialysis technology, a lifeline for millions, has remained fundamentally unchanged for over half a century. This outdated model places an enormous burden on patients, healthcare systems, and the environment.

We believe that dialysis can be hugely improved, to the point of a miniaturized device with better blood purification that forms an implantable artificial kidney that is smart (selective filtering), personalized (biosensors), efficient (optimized clearance and ultrafiltration) and low cost (affordable for patients worldwide).

We are a central hub for artificial kidney innovation fostering research and business collaborations to advance novel dialysis systems and bring new developments to patients and the market.

We focus on the development of implantable kidney systems and advanced dialysis solutions, supported by a large network of collaborators across technology, chemistry, engineering, and medicine.

Our testlab enables the testing of novel methods for artificial kidneys and dialysis innovation. We can simulate dialysis experiments, validate toxin removal and blood compatibility, and provide both in-vitro and in-vivo preclinical setups for comprehensive validation. The testlab is part of NXTGEN Hightech.

UNIVERSITY OF TWENTE.



Joshua Loessberg-Zahl

Technical Programme Manager

+31 6 2844 8314

j.t.loessberg-zahl@utwente.nl



Sanne de Wit

Operations and Programme Manager

+31 6 8136 9385

s.dewit@utwente.nl

University of Twente

The University of Twente is committed to combining our entrepreneurial mindset and personal approach with technological innovation across disciplines. We put society's needs central, leading to our strong focus on technology development for a healthy, safe, and climate-positive future. We foster excellent research to make pivotal contributions to the state of the art in our impact domains. This approach has led us to become one of the world's top research institutes in nanotechnology and one of the leading innovation hubs in the healthtech domain with state-of-the-art infrastructure for health and chip technology.

Joint Innovation Centre of University of Twente and TNO Bio/MicroSystems Centre is a Joint Innovation Centre co-created by University of Twente and TNO. We are dedicated to improving healthcare through technological innovation projects with key stakeholders. At Bio/MicroSystems Centre, we offer industry insights, high tech facilities and deep expertise that bridges the gap between technology and biology. We develop new, application-driven microphysiological systems and the methodologies needed to bring them to market. We accelerate the innovations of our partners by delivering standardized and scalable technologies.

Online information

[LinkedIn University of Twente](#)

[Website Organ-On-Chip Centre Twente](#)

[Website Bio/MicroSystems Centre](#)

University of Twente

Drienerlolaan 5

7522 NB Enschede

The Netherlands

<https://utwente.nl>



V I V A R T - X



Dan Jing Wu

CEO & Co-Founder

dj.wu@vivart-x.com

VivArt-X

VivArt-X is focussing on regenerative medicine in women's health. Our lead indication will revolutionize breast reconstructive surgery in women who have undergone breast tissue removal after breast cancer diagnosis. 1 in 7 women will develop breast cancer during her life. Approximately 50% of the 2 million breast cancer patients worldwide need cancerous tissue removal, and require breast reconstructive surgery. The estimated global market of breast reconstructive surgery is 2.7 billion in 2022, with a CAGR of 10%.

Currently, the most promising reconstructive technique is fat grafting. Using patient's own fat as donor and minimizes the need for complex surgical approaches. However, 50-60% of the transplanted fat cells will die within months, owing to bad cell engraftment and loss of blood supply. The impact of physical and emotional pain of postoperative breast cancer patients is correlated to the reconstruction strategy and recovery time. Therefore, there is an unmet need for a new breast reconstructive method so that surgeons can restore, reconstruct and regenerate breast tissue predictably with long term potential that contributes to an improved quality of breast cancer patient's life without physical or psychological discomfort.

VivArt-X offers a revolutionary, degradable biomaterial to achieve excellent cell engraftment, which results in personalized breast reconstruction and ultimately regeneration.

Online information

[LinkedIn VivArt-X](#)

VivArt-X

Het Eeuwse 57

5612 AS Eindhoven

The Netherlands

<http://www.vivart-x.com>



Hightech / Semicon



Johan Beukema

Managing Partner

+31 6 5110 0938

johan.beukema@bciglobal.com

Buck Consultants International

BCI Global (Buck Consultants International) is a leading specialized consultancy active in international expansion strategies, manufacturing footprint optimization, location strategy & site selection as well as supply chain and logistics.

In business for 40 years, our headquarters are in The Netherlands and we have own teams and offices across North America (4 offices) and Asia (Singapore, Shanghai, Gurugram/India).

Our team of 75 own professionals supports our clients around the globe and covers a variety of industries including strong track records in high tech & semicon as well as biotech / biopharma.

We have a strong customer base in Switzerland and are looking to expand our relationships with companies and organizations in Switzerland.

Online information

[LinkedIn Johan Beukema](#)

Buck Consultants International

Kerkenbos 1031

6546 BB Nijmegen

The Netherlands

<https://www.bciglobal.com>



Charilos Karambalis

Sales Manager

+31 6 4842 4183

c.karambalis@ceratec.nl



Haske van Zadelhoff

Business Development

+31 6 5496 6909

h.vanzadelhoff@ceratec.nl

Online information

[LinkedIn Ceratec Technical Ceramics](#)

[Video Brand story 2023](#)

Ceratec Technical Ceramics

Poppenbouwing 35

4191 NZ Geldermalsen

The Netherlands

<http://www.ceratec.nl>

Ceratec Technical Ceramics

At Ceratec Technical Ceramics, we specialize in the development and production of high-performance ceramic solutions tailored to meet the unique needs of various industries. Our team is dedicated to innovating and advancing ceramic technology, ensuring that we provide our clients with exceptional products that enhance their operational efficiency.

We pride ourselves on our commitment to quality and precision, allowing us to build long-lasting partnerships with businesses looking for reliable and sustainable technical ceramic applications. Together, we are shaping the future of material science in a wide range of applications.



Bas Klaver

Business Development

+31 6 1536 8468

bas.klaver@demcon.com

Demcon

Demcon high-tech systems is a full-service Engineering-as-a-Service provider for the development, realization and testing of customized (opto-)mechatronic solutions. We believe that every technical challenge has a solution and we are committed to enabling our customers to be successful.

We serve OEMs, start-ups and scale-ups in a diverse range of industries and continue to build our track record within the fields of Semicon, Aerospace, Quantum technology, Big science, Measurement & Control, Energy transition and Agri & Food.

Online information

[LinkedIn Demcon High-Tech Systems](#)

Demcon

Institutenweg 25

7521 PH Enschede

The Netherlands

<https://www.demcon.com>

**Peter-Jan Hendriks**

Manager Semicon Cluster

+31 6 5582 3892

pj.hendriks@hightechnl.nl

**Heleen Kamerman**

Manager Communication

+31 6 2706 8911

heleen.kamerman@hightechnl.nl

Online information

[LinkedIn Peter-Jan Hendriks](#)

High Tech NL

High Tech NL is the national industry association for the Dutch semiconductor and high-tech industry, driving innovation by connecting companies and knowledge institutions. From the High Tech Campus Eindhoven, we boost the ecosystem by encouraging collaboration—both nationally and internationally. We focus on four domains: Semiconductors, Robotics, Life Sciences, and Energy.

High Tech NL Semicon is also one of the driving forces behind the Chip NL Competence Center, participates in various projects such as NXTGen-Semicon, and is the initiator of the Semicon Board (Coalition of the Willing), where we, together with major industry players and several EU countries, guide the semiconductor industry in its next steps.

HighTech NL

High Tech Campus 27

5656 AE Eindhoven

The Netherlands

<https://www.hightechnl.nl/>



Ralph Stassen

CCO
+31 6 3177 6360
rstassen@hittech.com



Martijn Leijten

Business Development Manager
+31 6 4376 9278
mleijten@hittech.com

Hittech Group

Hittech Group is a global partner in turn-key development and contract manufacturing of mission-critical (opto-)mechatronic systems, modules, and components. We serve high-tech sectors such as semiconductor equipment, analytical equipment, medical equipment and robotics & industrial automation. Many of our solutions operate in vacuum and ultra-clean environments, where contamination control and mechanical accuracy are crucial.

Vacuum technology, optomechanics, and precise moving mechatronics are a core area of expertise across the Hittech Group. We have extensive experience in the design, engineering, and production of vacuum-compatible components and assemblies. This includes ultra-clean manufacturing, high-precision machining, surface treatment, and complex cleanroom assembly—particularly for semiconductor and analytical equipment applications.

At Hittech, we don't just produce—we partner with OEMs from the earliest development stages. Through co-engineering, Design for Manufacturing (DfM), Value Engineering, and advanced quality control, we deliver innovative, manufacturable solutions tailored to the most demanding requirements. Our flexible operations support everything from single prototypes to large-scale production—ranging from delicate modules to fully integrated systems.

With facilities in the Netherlands, Germany, and Malaysia, Hittech combines deep technical expertise with a global supply chain footprint.

Online information

[LinkedIn Hittech Group](#)

Hittech Group

Laan van Ypenburg 60
2497 GB The Hague
The Netherlands
<https://www.hittech.com/>

Holland High Tech

Global Challenges.
Smart Solutions



Peter Stolk

Chairman

+31 6 1875 9017

peter.stolk@hollandhightech.nl

Holland High Tech

Holland High Tech is the Top Sector High Tech Systems and Materials (HTSM), one of the ten top sectors of installed by Dutch Ministry of Economic Affairs.

Holland High Tech's ecosystem consists of 89,000 companies employing more than 500,000 hightech professionals. Multinationals, SMEs, start-ups and scale-ups that together represent 165 billion euros in production value and over 70 billion euros in export value.

In a framework of 10 innovation domains we offer structural solutions to societal challenges and create economic growth. Holland High Tech's overall aim is to stimulate international innovation, and cooperation. In our extensive ecosystem, businesses, knowledge institutions and government cooperate intensively in innovation-focused in public-private partnerships.

Teams of Holland High Tech experts develop (key) enabling technologies focussed on the National Technology Strategy - among which are Quantum technology, Optical systems and Integrated Photonics, Mechatronics and Optomechatronics, Semicon, Artificial Intelligence & Data, Imaging Technologies, Process Technology (including process intensification) and Energy Materials.

Online information

[LinkedIn Peter Stolk](#)

[Video Holland High Tech](#)

Holland High Tech | TKI HTSM

Winthontlaan 2

3526 KV Utrecht

The Netherlands

<https://hollandhightech.nl>



Maurice Janssen

Founder & CEO

+31 6 1105 0769

maurice.janssen@massspecpecd.com

Online information

[LinkedIn Maurice Janssen](#)

[Website AmsterdamPiezoValve](#)

MassSpecpecD

Langenkampweg 101

7522 LL Enschede

The Netherlands

www.massspecpecd.com

MassSpecpecD

Our main mission at MassSpecpecD BV is the development of a novel analytical instrument for direct and ultra-sensitive Mass Spectrometric measurement of the enantiomeric composition of chiral molecules. The new MS spectrometer employs laser-based PhotoElectron Circular Dichroism, PECD. This explains the last 4-letter part of our company's name, the capital letters S (Sinister) and D (Dexter) in our name reflect the two enantiomers in chiral molecules and are nicely placed Left and Right, MassSpecpecD.

We are collaborating with various companies in Laboratory Instrumentation and with world-leading scientists to develop the first commercial Mass Spectrometer employing MS-PECD technology. The novel analytical chiral MS-instrument is marketed for commercial enterprises in the Food, Flavor & Fragrances, Pharmaceuticals and Agro-Chemicals Industries and for academic & research institutes in novel (analytical & medical) applications employing chiral molecules.

We also market, sell and further develop the Amsterdam Piezo Valve product and its applications, in close collaboration with Tec4Science/TechCentre at Vrije Universiteit Amsterdam and the MESA+ Institute/Nanolab (prof. Gardeniers-group) at the University of Twente.

The innovative AmsterdamPiezoValve (APV) product has been purchased by many (> 150) research groups, institutes and companies worldwide (Europe, USA, China, Japan, South-Korea, Israel, Argentina, e.g. in Switzerland purchased by PSI-Villingen, ETH-Zurich, EPFL-Lausanne and the University of Basel) and the APV-equipment is used in a wide range of applications in research and industry. For instance, in FreeElectronLaser beam diagnostics (SwissFEL, SACLA), Velocity Map Imaging spectroscopy in Atomic, Molecular and Optical Physics, Physical Chemistry and Analytical Chemistry, High Harmonic Generation, EUV/XUV generation, Laser Desorption, metastable and Ion discharge sources. The APV product was an essential part of the research in the groups of two Physics Nobel Laureates 2023, Prof. Anne L'Huillier at Lund University, Sweden, and Prof. Pierre Agostini at Ohio State University, USA.



Maurice Vleugels

Sales Manager

+31 6 2525 8748

maurice.vleugels@nedinsco.nl

Online information

[LinkedIn Maurice Vleugels](#)

[Video Nedinsco](#)

Nedinsco

Jan van Riebeeckweg 5

5928 LG Venlo

The Netherlands

<https://nedinsco.com/>

Nedinsco

Nedinsco stands at the forefront of opto-mechatronics, specializing in the development and production of advanced opto-mechatronic systems.

By combining precision engineering, optical technologies, and high-level system integration, we deliver solutions that provide exceptional detection, visualization, and control—even under the most demanding conditions.

Our Distinctive Approach

What makes Nedinsco unique is our deep expertise in seamlessly integrating optical components (such as lenses, mirrors, and sensors) with cutting-edge mechatronic systems. This synergy enables the creation of high-precision, extreme ruggedized, and reliable systems for critical applications across defense, security, semiconductor, and scientific industries. Our strong in-house R&D, state-of-the-art assembly, and High-Tech Assembly facilities in the Netherlands ensure the highest quality and performance at every stage.

Thanks to our legacy of over a century of technological excellence..., we harness a broad spectrum of expertise, cutting-edge technologies, and scalable production capabilities—delivering tailored solutions for the most demanding high-tech challenges.

Our solutions enable:

- Ultra-precise positioning and stability (essential for metrology, semiconductor lithography, and scientific instrumentation)
- Vision systems for automated inspection, measurement, and situational awareness
- Adaptive optics for high-end imaging and laser-based communication systems
- Custom sensors and actuators integrated for real-time feedback and control

Our advanced opto-mechatronic systems are vital in segments such as:

- Semiconductor manufacturing and inspection
- High-end scientific and medical instrumentation
- Space and astronomy equipment
- Defense and security applications



Jean-Pierre Kempeneers

Chief Corporate Affairs
+31 6 1171 8553

jean-
pierre.kempeneers@nexperia.com

Nexperia

Headquartered in the Netherlands, Nexperia is a global semiconductor company with a rich European history, originated from Royal Philips and NXP and has over 12500 employees across Europe, Asia, and the United States. The mother-holding Wingtech is listed in Shanghai. Nexperia develops and produces highly energy efficient semiconductors which enable the basic functionality of a broad set of commercial electronic designs – from automotive and industrial to mobile and consumer applications.

The company serves a global customer base, shipping more than 110 billion products annually. We produce 1:10 chips in the world. These products are recognized as benchmarks in efficiency – in process, size, power and performance. Nexperia's commitment to innovation, efficiency and stringent industry requirements are evident in its extensive

IP portfolio, its expanding product range and its certification to IATF 16949, ISO 9001, ISO 14001 and ISO 45001 standards. Nexperia has production sites in Hamburg, Manchester, China, Malaysia and the Philippines.

Online information

[LinkedIn Jean-Pierre Kempeneers](#)

Nexperia

Jonkerbosplein 52
6534 AB Nijmegen
The Netherlands
<https://www.nexperia.com/>



Robbin van Zanten

Sr. Account Manager
+31 6 2272 7600
zanten.r@nijdra.nl

Nijdra Group

At Nijdra, we manufacture first-class precision mechanical components and mechatronic modules every day. In doing so, we take care of the (bio)medical, analytical, optical and pharmaceutical industries as well as the semiconductor sector worldwide.

We don't have a product catalogue; we make what the customer needs. From the smallest parts at the heart of machines that matter, to fully assembled table-top models. Where precision is often literally vital. It is done in our state-of-the-art factories: turning, milling and grinding. With micron-level precision. Precision. To the max!

But there is more! Our proud family business has been operating for three generations now. That vast experience in the high-tech industry means we can add value from development all the way to the final product. Co-engineering, production, assembly..., the customer decides. We value long-term relationships; intensive collaboration guarantees the best quality.

Online information

[LinkedIn Robbin van Zanten](#)

[LinkedIn Nijdra Group](#)

[Video Nijdra](#)

Nijdra Group

Bamestraweg 31
1462 VM Middenbeemster
The Netherlands
<http://www.nijdra.com/>



Rik Wetzels

System Architect

+31 6 4993 7195

rik.wetzels@nobleo.nl

Nobleo

We are an international team of engineers, thinkers, and doers, based in Brainport Eindhoven to help our customers build a better and safer tomorrow through technology.

We support our customers throughout 3 key areas in engineering: • Autonomous – Solutions relieving us of dirty, dull, and dangerous jobs • Intelligent – Artificial Intelligence helping humans to make smart decisions • Systems – Engineering to create effective and efficient machines All in close collaboration with our customers, because tomorrow's challenges are not to be faced alone.

Nobleo is developing and testing machine learning solutions for the automated inspection of high-mix low-volume production of Photonic wafers (PIC's) in collaboration with Lionix, PITC and Ligentec.

Looking for opportunities to apply our machine learning algorithms in adjacent domains (MEMS, Graphene, Microfluidics and Photonics).

Online information

[LinkedIn Rik Wetzels](#)

Nobleo

Heggeranklaan 1

5643 BP Eindhoven

The Netherlands

<http://www.nobleo-technology.nl>



Frank Wissink

Head of Sales

+31 6 1393 5126

frank.wissink@pronexos.com

Pronexos

Pronexos is a leading manufacturer of high quality carbon fibre products and a supplier of specialist manufacturing products and services to high-tech industries. Our products and services include:

The main processes & services are:

- Electron Beam Welding,
- Heat treatment & Brazing,
- Flow Forming (Cold forming),
- Carbon Fibre Reinforced Polymer applications.

Pronexos is a trade name for Enrichtment Technology Nederlands BV which designs, qualifies, manufactures and install Ultracentrifuges to enrich Isotopes for Nuclear & Medical applications.

Pronexos

Planthofsweg 77

7601 PJ Almelo

The Netherlands

<https://www.pronexos.com/>

Provincie Noord-Brabant



Carl Dortmans

Policy Advisor International Affairs
+31 6 1582 6380
ccdortmans@brabant.nl

Online information

[LinkedIn Carl Dortmans](#)

Province of Noord-Brabant

Brabantlaan 1
5216 TV 's-Hertogenbosch
The Netherlands
<https://www.brabantisbright.nl>

Province of Noord-Brabant

Brabant is a prime location in the Netherlands, offering rapid and direct access to key markets in Europe and the rest of the world. A profound legacy of innovative excellence was laid down by the global multinational Philips and continues to permeate the region today across various dynamic industry sectors, working together, collaborating, and co-creating solutions for the great challenges of our times.

The region of Brabant embraced the legacy of high-tech innovation and used it as a foundation to build the #1 innovative region for IT in the Netherlands. One of the region's essential resources is its 79,000 highly educated IT professionals, with 42,360 directly working in IT. In addition, the region boasts a high degree of specialization with various IT technologies, such as 3D systems, smart industrial technologies, smart medical applications, and smart agriculture.

The high-tech and semiconductor industries are important for the economy and employment in Brabant. 20% of the Dutch export value (57 billion, or 23% of total Dutch exports) comes from Brabant, mainly thanks to high-tech and semiconductor industry. A company such as ASML had ca. 42,000 employees worldwide at the end of 2023, of which ca. 23,000 in the Netherlands.

Some of the companies in the high-tech semiconductor program are also connected to Brabant; VDL ETG and IBM (through its CIC) have operational activities in Brabant. VDL Enabling Technologies Group is part of the VDL Group, headquartered in Eindhoven, North Brabant. In addition, Besi has its headquarters elsewhere in the Netherlands (Duiven). The Dutch entity Besi Netherlands B.V. operates under BE Semiconductor Industries N.V. and develops and manufactures advanced semiconductor assembly machines under the brand name Fico. Roche is active in the Netherlands through divisions such as Roche Diagnostics Nederland B.V., located in Almere. In addition, IBM has a Client Innovation Center in Eindhoven, which serves as an innovation and collaboration hub with Dutch companies (related to IBM Research activities).

UNIVERSITY OF TWENTE.



Wilfred van der Wiel

Professor of NanoElectronics & Co-Director BRAINS

+31 6 3018 2641

W.G.vanderWiel@utwente.nl

University of Twente - BRAINS

The mission of the Center for Brain-Inspired Computing (BRAINS) is to develop efficient hardware for information processing. We combine core expertise in nanoscience and nanotechnology with expertise from computer science, applied mathematics, artificial intelligence and neuroscience, to lay the scientific foundations for a new generation of powerful, energy-efficient computing hardware. Artificial and biological neural networks, in particular the brain, form a main inspiration. It is our ambition to understand the key features underlying the functioning of the brain, and translate those into hardware.

Our research includes, but is not limited to reconfigurable, memristive and adaptive materials, artificial neurons and synapses, evolution in materia and neuromorphic architectures. We look at the connection between our hardware and conventional (CMOS) electronics, and at the interface with biological systems. Societal implications and philosophical aspects are studied.

BRAINS is an inter-faculty center of the University of Twente with investigators from the MESA+ Institute for Nanotechnology, the Digital Society Institute and the Faculty of Behavioural, Management and Social sciences. The center aims to provide coherence and visibility. With its focus and critical mass BRAINS hopes to be a valuable partner in national and international consortia.

Online information

[University of Twente – Wilfred van der Wiel](#)

[LinkedIn Wilfred van der Wiel](#)

University of Twente

Drienerlolaan 5
7522 NB Enschede
The Netherlands

<https://www.utwente.nl/>



Markjan Vermeer

Managing Director

+31 6 1055 9162

markjan.vermeer@vdlletg.com

VDL Enabling Technologies Group

As a global development and manufacturing company, our customers are leading companies in the semiconductor, analytical, medical and space industry. Our products are characterized by their high complexity and relatively low production runs.

We provide systems and modules such as high end vacuum equipment, fragile substrate handling and accurate positioning systems and beam delivery (E-beam, Ion beam, laser beam,) applying world-class manufacturing technologies.

To control and optimize the physical conditions in which the customer's process takes place, we proactively invest in and innovate relevant technologies such as:

- Contamination Control
- MagLev
- Data Science
- Opto-mechatronics
- (in situ) magnetics
- Motion control
- Vacuum control
- Thermal control
- Super conductivity and cryogenics
- DFM: Joining techniques
- DFM: Ultra-High Precision
- DFM: Additive manufacturing
- DFM: Adhesives

Facts & Figures

- 12 locations in 6 countries
- 5,000 employees
- 700 FTE Technology & Development
- 4,300 FTE contract manufacturing
- > 250,000 m² production area
- >50,000 m² cleanroom

Online information

[LinkedIn Markjan Vermeer](#)

[LinkedIn VDL Enabling Technologies Group](#)

VDL Enabling Technologies Group

De Schakel 22

5651 GH Eindhoven

The Netherlands

<https://www.vdlletg.com/en>



Henk Akkermans

Director

+31 6 5379 0009

ha@worldclassmaintenance.com

World Class Maintenance

At Stichting World Class Maintenance, we are dedicated to advancing maintenance practices across industries by fostering collaboration and sharing knowledge among professionals. Our mission is to promote a culture of excellence in maintenance through education, certification, and the development of best practices. By connecting industry leaders and innovators, we aim to drive continuous improvement and sustainability in maintenance operations worldwide. Together, we are transforming maintenance into a strategic asset for businesses.

World Class Maintenance

Boschstraat 35

4811 GB Breda

The Netherlands

<http://www.worldclassmaintenance.com>

Contact details

Contact details

Ministry of Foreign Affairs

PO Box 20061

2500 EB The Hague

www.government.nl/ministries/bz



Michiel Sweers

Vice Minister for Foreign
Trade



Marc Hasselaar

Deputy Director International
Enterprise Department



Margot Bolhuis

Policy Officer International
Enterprise Department

Ministry of Agriculture, Nature and Food Quality

PO Box 20401

2500 EK The Hague

[www.government.nl/ministries/ministry-
of-agriculture-nature-and-food-quality](http://www.government.nl/ministries/ministry-of-agriculture-nature-and-food-quality)



Bas de Waard

Policy Advisor International -
Transition Program
s.h.dewaard@minlnv.nl

Ministry of Health, Welfare and Sport

Parnassusplein 5

2511 VX The Hague

[https://www.government.nl/ministries/
ministry-of-health-welfare-and-sport](https://www.government.nl/ministries/ministry-of-health-welfare-and-sport)



Wouter Leijts

Policy Officer Biotechnology
wt.leijts@minvws.nl

Contact details

Ministry of Economic Affairs/
Netherlands Enterprise Agency
PO Box 93144
2509 AC The Hague
<https://english.rvo.nl>



Niels van Leeuwen
Sr. Advisor International R&D
Cooperation
niels.vanleeuwen@rvo.nl



Sandra Pompe
Project Manager Economic
Missions
sandra.pompe@rvo.nl



Maurits Berger
Project Manager Economic
Missions
Maurits.berger@rvo.nl
[LinkedIn Maurits Berger](#)

Contact details

VNO-NCW | MKB Nederland

PO Box 93002

2509 AA The Hague

www.vno-ncw.nl



Ingrid Thijssen

President VNO-NCW



Kees Bakhuizen

Spokesperson

Bakhuis@vnoncw-mkb.nl



Mirian Keuning

Deputy Director International
Affairs

keuning@vnoncw-mkb.nl



Isabelle Diniz

International Affairs Officer

diniz@vnoncw-mkb.nl

Contact details

Embassy of the Kingdom of the Netherlands

Seftigenstrasse 7

3007 Bern

Switzerland

<https://www.netherlandsandyou.nl/web/switzerland>



Karin Mössenlechner

Ambassador

ben-cdp@minbuza.nl



Leonoor van Munster

Deputy Ambassador

leonoor-van.munster@minbuza.nl



Saskia Harthoorn

Senior Advisor, Entrepreneurship,
Innovation

saskia.harthoorn@minbuza.nl



Anita van Rozen

Senior Advisor, Entrepreneurship,
Innovation

anita-van.rozen@minbuza.nl



Eva van Vliet

Policy Officer Digital &
Preventative Health

Eva-van.vliet@minbuza.nl

To learn more on how The Netherlands is
cooperating with its international counterparts:

Visit [NL Platform](#) or follow us on [LinkedIn](#)



Netherlands